Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant

Unity Health Toronto

$662,450.00

Ultrasound-targeted gene therapy for heart failure

FY 2008-09

Summary
Despite advances in medical and surgical therapies, the morbidity and mortality of patients with chronic coronary artery disease and heart failure remains high. For patients who fail to improve with conventional treatments and whose heart function continues to deteriorate, novel therapies to improve cardiac pumping function are needed. Promising new techniques involves either genes, or special cells called "progenitor" cells. These cells are derived from the blood or bone-marrow, and have the ability to develop into new vessels or heart muscle cells. We have developed novel ultrasound techniques using microbubbles that can be targeted to the heart, and can be used to deliver gene or cell therapy, without the use of direct injections. A non-invasive means of delivery would facilitate an easy and safe method for repeated delivery in patients. This present research, if successful, will lead to a non-invasive method of delivering novel treatments to promote new vessel formation, limit heart muscle death and improve cardiac function in patients with severe symptomatic heart failure.
Program
Operating Grant
Location
Ontario, Canada
Recipient Type
Other
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
171430
Name
Leong-Poi Howard M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Cardiovascular System - B: Heart and Circulation
Projecttitle
Ultrasound-targeted gene therapy for heart failure
Programtype2
Operating Grants
Orgnameinp2
Unity Health Toronto
Cihramount2
$662,450
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Chronic Ischemia; Gene Delivery; Heart Failure; Progenitor Cells; Targeted Microbubbles; Therapeutic Angiogenesis
Abstract
Despite advances in medical and surgical therapies, the morbidity and mortality of patients with chronic coronary artery disease and heart failure remains high. For patients who fail to improve with conventional treatments and whose heart function continues to deteriorate, novel therapies to improve cardiac pumping function are needed. Promising new techniques involves either genes, or special cells called "progenitor" cells. These cells are derived from the blood or bone-marrow, and have the ability to develop into new vessels or heart muscle cells. We have developed novel ultrasound techniques using microbubbles that can be targeted to the heart, and can be used to deliver gene or cell therapy, without the use of direct injections. A non-invasive means of delivery would facilitate an easy and safe method for repeated delivery in patients. This present research, if successful, will lead to a non-invasive method of delivering novel treatments to promote new vessel formation, limit heart muscle death and improve cardiac function in patients with severe symptomatic heart failure.
Competitiondate
200809
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Leong-Poi, Howard M
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $662,450~ $0~
Unity Health Toronto - $662,450 Grant (2008-09) | Canada Spends